These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32244346)

  • 21. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
    Verkman AS; Lukacs GL; Galietta LJ
    Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability.
    Meng X; Clews J; Kargas V; Wang X; Ford RC
    Cell Mol Life Sci; 2017 Jan; 74(1):23-38. PubMed ID: 27734094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.
    Molinski SV; Ahmadi S; Hung M; Bear CE
    J Biomol Screen; 2015 Dec; 20(10):1204-17. PubMed ID: 26385858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New and emerging targeted therapies for cystic fibrosis.
    Quon BS; Rowe SM
    BMJ; 2016 Mar; 352():i859. PubMed ID: 27030675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CFTR pharmacology.
    Zegarra-Moran O; Galietta LJ
    Cell Mol Life Sci; 2017 Jan; 74(1):117-128. PubMed ID: 27704174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular modelling approaches for cystic fibrosis transmembrane conductance regulator studies.
    Odolczyk N; Zielenkiewicz P
    Int J Biochem Cell Biol; 2014 Jul; 52():39-46. PubMed ID: 24735712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The implications of CFTR structural studies for cystic fibrosis drug development.
    Callebaut I; Hoffmann B; Mornon JP
    Curr Opin Pharmacol; 2017 Jun; 34():112-118. PubMed ID: 29096277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
    Roomans GM
    Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ion Channel Modulators in Cystic Fibrosis.
    Gentzsch M; Mall MA
    Chest; 2018 Aug; 154(2):383-393. PubMed ID: 29750923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library.
    Orro A; Uggeri M; Rusnati M; Urbinati C; Pedemonte N; Pesce E; Moscatelli M; Padoan R; Cichero E; Fossa P; D'Ursi P
    Eur J Med Chem; 2021 Mar; 213():113186. PubMed ID: 33472120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis.
    Wang X; Liu B; Searle X; Yeung C; Bogdan A; Greszler S; Singh A; Fan Y; Swensen AM; Vortherms T; Balut C; Jia Y; Desino K; Gao W; Yong H; Tse C; Kym P
    J Med Chem; 2018 Feb; 61(4):1436-1449. PubMed ID: 29251932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
    Boucherle B; Bertrand J; Maurin B; Renard BL; Fortuné A; Tremblier B; Becq F; Norez C; Décout JL
    Eur J Med Chem; 2014 Aug; 83():455-65. PubMed ID: 24992073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unmet needs in cystic fibrosis.
    Rubin BK
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):49-52. PubMed ID: 30063865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.